Patent ID: 7473708

Claim:
A method for the treatment of an enveloped RNA viral infection in a human or animal comprising administering to a human or animal in need of such treatment, a pharmacologically acceptable therapeutically effective amount of exogenous LTB 4 agent selected from the group consisting of 5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid, 5-hydroxy-6,8,11,14-eicosatetraenoic acid, 20,20,20-trifluoromethyl-LTB 4 ; 19-methyl-LTB 4 , 19,19-dimethyl-LTB 4 , 19-fluoro-LTB 4 , 19,19-difluoro-LTB 4 , 18,20-difluro-LTB 4 , 20-fluoro-LTB 4 , 3-thio-LTB 4 , 3-hydroxy-LTB 4 , 3-methyl-LTB 4 , 3,3-dimethyl-LTB 4 , 3-fluoro-LTB 4 , 3,3-difluoro-LTB 4 , 2,3-difluoro-LTB 4 ; 14,15-dihydro-LTB 4 (“LTB 3 ”), 17,18-dehydro-LTB 4 (“LTB 5 ”), 19-hydroxy-LTB 4 , 20-hydroxy-LTB 4 and 5(R)-hydroxy, 5-keto, 5(S)hydroperoxy, 5(R)-hydroperoxy and 5-deoxy analogs thereof; LTB 4 methyl ester; 5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid; 20,20,20-trifluoromethyl-LTB 4 ; and 5S,12R-dihydroxy-6,8,10,14(Z,E,E,Z)-eicosatetraenoic acid and any salts and mixtures thereof.